Literature DB >> 16815256

Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.

Olcay Tatar1, Annemarie Adam, Kei Shinoda, Peter Stalmans, Claus Eckardt, Matthias Lüke, Karl Ulrich Bartz-Schmidt, Salvatore Grisanti.   

Abstract

PURPOSE: To examine the impact of photodynamic therapy (PDT) on pigment epithelium derived factor (PEDF) expression in human choroidal neovascularization (CNV) membranes with regard to vascular endothelial growth factor (VEGF) expression.
DESIGN: Interventional case series.
METHODS: Retrospective review of interventional case series of 42 patients (42 eyes) who underwent removal of CNV. CNV was secondary to age-related macular degeneration (AMD) in all cases. Fifteen patients were treated with PDT, 3 to 246 days before surgery. CNV were stained for CD34, CD105, cytokeratin 18, VEGF, and PEDF. Twenty-seven CNV without previous treatment were used as control.
RESULTS: Specimens without pretreatment disclosed varying degrees of vascularization, VEGF, and PEDF expression by different cells. Specimens treated by PDT, three days previously showed mostly occluded vessels lined with damaged endothelial cells (EC). In contrast, specimens excised at later time points after PDT were highly vascularized with healthy EC. This chronology was associated with an impressive VEGF immunoreactivity increased considerably in retinal pigment epithelial cells as well as significantly reduced PEDF expression in EC and stroma.
CONCLUSIONS: PDT induces a selective vascular damage in CNV. The effectiveness of PDT, however, seems to be jeopardized by a rebound effect initiated by an enhanced VEGF and reduced PEDF expression in CNV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815256     DOI: 10.1016/j.ajo.2006.01.085

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  28 in total

1.  Towards a rational approach to combination therapy for neovascular age-related macular degeneration.

Authors:  Jorge G Arroyo
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

2.  Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.

Authors:  Olcay Tatar; Kei Shinoda; Annemarie Adam; Tillmann Eckert; Claus Eckardt; Klaus Lucke; Christoph Deuter; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

3.  Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Shixian Long; Shizhou Huang; Meng Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-15       Impact factor: 3.117

4.  Expression and purification of functional epitope of pigment epithelium-derived factor in E. coli with inhibiting effect on endothelial cells.

Authors:  Qing Gong; Xia Yang; Weibin Cai; Guoquan Gao; Zhonghan Yang
Journal:  Protein J       Date:  2010-04       Impact factor: 2.371

5.  Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.

Authors:  Isao Nakata; Akitaka Tsujikawa; Kenji Yamashiro; Atsushi Otani; Sotaro Ooto; Yumiko Akagi-Kurashige; Naoko Ueda-Arakawa; Daisuke Iwama; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-25       Impact factor: 3.117

6.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-05       Impact factor: 3.117

7.  Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Tillmann Eckert; Gábor B Scharioth; Micheal Klein; Efdal Yoeruek; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

8.  Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Noriaki Shimada; Muka Moriyama; Wakako Hara; Takeshi Yoshida; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-16       Impact factor: 3.117

9.  Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.

Authors:  Farzin Forooghian; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2009-06       Impact factor: 4.256

10.  Effect of posterior juxtascleral triamcinolone acetonide on the efficacy and choriocapillaris hypoperfusion of photodynamic therapy.

Authors:  Aya Iriyama; Ryo Obata; Yuji Inoue; Hidenori Takahashi; Yasuhiro Tamaki; Yasuo Yanagi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-06       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.